Hepatobiliary Infections After Solid Organ or Hematopoietic Cell Transplantation

Chapter

Abstract

Liver and biliary tract infections are common after solid organ (SOT) or hematopoietic cell transplantation (HCT). SOT recipients who receive liver grafts develop more liver problems than recipients of other organs, but liver issues such as gallstones, viral infections, and cholestasis related to drugs and infection are common after kidney, lung, heart, and pancreas transplants. Hematopoietic cell recipients must also face the toxicity of myeloablative conditioning regimens, absence of cellular immunity pending engraftment, acute and chronic GVHD, and delayed immune reconstitution. When hepatobiliary problems develop after a transplant, there is a wide differential diagnosis that encompasses both infectious and noninfectious causes, and sometimes, both simultaneously.

Keywords

Solid organ transplant Hematopoietic cell transplant Infection Diagnosis Treatment 

References

  1. 1.
    Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med. 2007;357:2601–14.PubMedCrossRefGoogle Scholar
  2. 2.
    Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363:2091–101.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Marty FM, Winston DJ, Rowley SD, et al. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med. 2013;369:1227–36.PubMedCrossRefGoogle Scholar
  4. 4.
    Aghemo A, Donato MF. Sofosbuvir treatment in the pre and post liver transplantation phase: the sooner, the better. Gastroenterology. 2015;148:13–6.PubMedCrossRefGoogle Scholar
  5. 5.
    Torres HACP, De Lima M, Friedman MS, Giralt S, Hammond SP, Kiel PJ, Masur H, McDonald GB, Wingard JR, Gambarin-Gelwan M. Hepatitis C virus infection among hematopoietic cell transplant recipients: American Society for Blood and Marrow Transplantation Task Force Recommendations. Biol Blood Marrow Transplant. 2015;21(11):1870–82.PubMedCrossRefGoogle Scholar
  6. 6.
    Vera A, Contreras F, Guevara F. Incidence and risk factors for infections after liver transplant: single-center experience at the University Hospital Fundacion Santa Fe de Bogota, Colombia. Transpl Infect Dis. 2011;13:608–15.PubMedCrossRefGoogle Scholar
  7. 7.
    Romero FA, Razonable RR. Infections in liver transplant recipients. World J Hepatol. 2011;3:83–92.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Kathuria P, Sakhuja V, Gupta KL, et al. Gastrointestinal complications after renal transplantation. 10 year data from a North Indian Transplant Center. ASAIO J. 1995;41:M698–703.PubMedCrossRefGoogle Scholar
  9. 9.
    Helderman JH, Goral S. Gastrointestinal complications of transplant immunosuppression. J Am Soc Nephrol. 2002;13: 277–87.PubMedGoogle Scholar
  10. 10.
    Logan AJ, Morris-Stiff GJ, Bowrey DJ, Jurewicz WA. Upper gastrointestinal complications after renal transplantation: a 3-yr sequential study. Clin Transplant. 2002;16:163–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Lucey MR, Terrault N, Ojo L, et al. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transpl. 2013;19:3–26.PubMedCrossRefGoogle Scholar
  12. 12.
    Pedersen M, Seetharam A. Infections after orthotopic liver transplantation. J Clin Exp Hepatol. 2014;4:347–60.PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Cervera C, Fernandez-Ruiz M, Valledor A, et al. Epidemiology and risk factors for late infection in solid organ transplant recipients. Transpl Infect Dis. 2011;13:598–607.PubMedCrossRefGoogle Scholar
  14. 14.
    San Juan R, Aguado JM, Lumbreras C, et al. Incidence, clinical characteristics and risk factors of late infection in solid organ transplant recipients: data from the RESITRA study group. Am J Transplant. 2007;7:964–71.PubMedCrossRefGoogle Scholar
  15. 15.
    Sterling RK. Management of gastrointestinal disease in liver transplant recipients. Gastrointest Endosc Clin N Am. 2001;11:185–97.PubMedGoogle Scholar
  16. 16.
    Kamar N, Selves J, Mansuy JM, et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med. 2008;358:811–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Pischke S, Suneetha PV, Baechlein C, et al. Hepatitis E virus infection as a cause of graft hepatitis in liver transplant recipients. Liver Transpl. 2010;16:74–82.PubMedCrossRefGoogle Scholar
  18. 18.
    Morales JM, Bloom R, Roth D. Kidney transplantation in the patient with hepatitis C virus infection. Contrib Nephrol. 2012;176:77–86.PubMedCrossRefGoogle Scholar
  19. 19.
    Moghaddam SM, Alavian SM, Kermani NA. Hepatitis C and renal transplantation: a review on historical aspects and current issues. Rev Med Virol. 2008;18:375–86.PubMedCrossRefGoogle Scholar
  20. 20.
    Baid-Agrawal S, Pascual M, Moradpour D, Somasundaram R, Muche M. Hepatitis C virus infection and kidney transplantation in 2014: what’s new? Am J Transplant. 2014;14:2206–20.PubMedCrossRefGoogle Scholar
  21. 21.
    Mahmoud IM, Elhabashi AF, Elsawy E, El-Husseini AA, Sheha GE, Sobh MA. The impact of hepatitis C virus viremia on renal graft and patient survival: a 9-year prospective study. Am J Kidney Dis. 2004;43:131–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Ghafari A, Sanadgol H. Impact of hepatitis B and hepatitis C virus infections on patients and allograft outcomes in renal transplant recipients: a single center study. Transplant Proc. 2008;40:196–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G. Hepatitis C virus antibody status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant. 2005;5:1452–61.PubMedCrossRefGoogle Scholar
  24. 24.
    Ridruejo E, Cusumano A, Diaz C, et al. Hepatitis C virus infection and outcome of renal transplantation. Transplant Proc. 2007;39:3127–30.PubMedCrossRefGoogle Scholar
  25. 25.
    Lopez-Medrano F, Fernandez-Ruiz M, Morales JM, et al. Impact of hepatitis C virus infection on the risk of infectious complications after kidney transplantation: data from the RESITRA/REIPI cohort. Transplantation. 2011;92:543–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Fabrizi F, Martin P, Dixit V, Messa P. Meta-analysis of observational studies: hepatitis C and survival after renal transplant. J Viral Hepat. 2014;21:314–24.PubMedCrossRefGoogle Scholar
  27. 27.
    Tsai SF, Shu KH, Ho HC, et al. Trend of outcomes in renal transplant recipients with hepatitis B virus: a longitudinal analysis using a national database. Transplant Proc. 2014;46:578–82.PubMedCrossRefGoogle Scholar
  28. 28.
    Lu K, Wang HP, Chen YS. Outcomes of kidney transplantation recipients with hepatitis in the antiviral therapy era: a single-center experience. Transplant Proc. 2014;46:460–3.PubMedCrossRefGoogle Scholar
  29. 29.
    Emori CT, Perez RM, Matos CA, et al. Acute exacerbation of chronic hepatitis B virus infection in renal transplant patients. Braz J Infect Dis. 2014;18:625–30.PubMedCrossRefGoogle Scholar
  30. 30.
    Czaja AJ. Diagnosis, pathogenesis, and treatment of autoimmune hepatitis after liver transplantation. Dig Dis Sci. 2012;57:2248–66.PubMedCrossRefGoogle Scholar
  31. 31.
    Jacob DA, Neumann UP, Bahra M, et al. Long-term follow-up after recurrence of primary biliary cirrhosis after liver transplantation in 100 patients. Clin Transplant. 2006;20:211–20.PubMedCrossRefGoogle Scholar
  32. 32.
    Campsen J, Zimmerman MA, Trotter JF, et al. Clinically recurrent primary sclerosing cholangitis following liver transplantation: a time course. Liver Transpl. 2008;14:181–5.PubMedCrossRefGoogle Scholar
  33. 33.
    Gautam M, Cheruvattath R, Balan V. Recurrence of autoimmune liver disease after liver transplantation: a systematic review. Liver Transpl. 2006;12:1813–24.PubMedCrossRefGoogle Scholar
  34. 34.
    deLemos AS, Schmeltzer PA, Russo MW. Recurrent hepatitis C after liver transplant. World J Gastroenterol. 2014;20:10668–81.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Neumann UP, Berg T, Bahra M, et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol. 2004;41:830–6.PubMedCrossRefGoogle Scholar
  36. 36.
    Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology. 2002;122:889–96.PubMedCrossRefGoogle Scholar
  37. 37.
    Wiesner RH, Sorrell M, Villamil F. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl. 2003;9:S1–9.PubMedCrossRefGoogle Scholar
  38. 38.
    Verna EC, Abdelmessih R, Salomao MA, Lefkowitch J, Moreira RK, Brown Jr RS. Cholestatic hepatitis C following liver transplantation: an outcome-based histological definition, clinical predictors, and prognosis. Liver Transpl. 2013;19:78–88.PubMedCrossRefGoogle Scholar
  39. 39.
    Mukherjee S. Natural history, risk factors and management of hepatitis C after liver transplantation. Inflamm Allergy Drug Targets. 2012;11:124–30.PubMedCrossRefGoogle Scholar
  40. 40.
    Samuel D, Feray C. Recurrent hepatitis C after liver transplantation: clinical and therapeutical issues. J Viral Hepat. 2000;7:87–92.PubMedCrossRefGoogle Scholar
  41. 41.
    Berenguer M. What determines the natural history of recurrent hepatitis C after liver transplantation? J Hepatol. 2005;42:448–56.PubMedCrossRefGoogle Scholar
  42. 42.
    Firpi RJ, Clark V, Soldevila-Pico C, et al. The natural history of hepatitis C cirrhosis after liver transplantation. Liver Transpl. 2009;15:1063–71.PubMedCrossRefGoogle Scholar
  43. 43.
    Jimenez-Perez M, Gonzalez-Grande R, Rando-Munoz FJ. Management of recurrent hepatitis C virus after liver transplantation. World J Gastroenterol. 2014;20:16409–17.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Hulskotte E, Gupta S, Xuan F, et al. Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. Hepatology. 2012;56:1622–30.PubMedCrossRefGoogle Scholar
  45. 45.
    Curry MP, Forns X, Chung RT, et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology 2015;148:100–7.e1.Google Scholar
  46. 46.
    Charlton M, Gane E, Manns MP, et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology. 2015;148:108–17.PubMedCrossRefGoogle Scholar
  47. 47.
    Pawlotsky JM. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology. 2014;146:1176–92.PubMedCrossRefGoogle Scholar
  48. 48.
    Aghemo A, De Francesco R. New horizons in hepatitis C antiviral therapy with direct-acting antivirals. Hepatology. 2013;58:428–38.PubMedCrossRefGoogle Scholar
  49. 49.
    Herzer K, Papadopoulos-Kohn A, Walker A, et al. Daclatasvir, Simeprevir and Ribavirin as a promising interferon-free triple regimen for HCV recurrence after liver transplant. Digestion. 2015;91:326–33.PubMedCrossRefGoogle Scholar
  50. 50.
    Kwo PY, Mantry PS, Coakley E, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med. 2014;371:2375–82.PubMedCrossRefGoogle Scholar
  51. 51.
    Skagen CL, Jou JH, Said A. Risk of de novo hepatitis in liver recipients from hepatitis-B core antibody-positive grafts—a systematic analysis. Clin Transplant. 2011;25:E243–9.PubMedCrossRefGoogle Scholar
  52. 52.
    Roche B, Samuel D. Prevention of hepatitis B virus reinfection in liver transplant recipients. Intervirology. 2014;57:196–201.PubMedCrossRefGoogle Scholar
  53. 53.
    Avelino-Silva VI, D'Albuquerque LA, Bonazzi PR, et al. Liver transplant from Anti-HBc-positive, HBsAg-negative donor into HBsAg-negative recipient: is it safe? A systematic review of the literature. Clin Transplant. 2010;24:735–46.PubMedCrossRefGoogle Scholar
  54. 54.
    Haagsma EB, van den Berg AP, Porte RJ, et al. Chronic hepatitis E virus infection in liver transplant recipients. Liver Transpl. 2008;14:547–53.PubMedCrossRefGoogle Scholar
  55. 55.
    Haagsma EB, Niesters HG, van den Berg AP, et al. Prevalence of hepatitis E virus infection in liver transplant recipients. Liver Transpl. 2009;15:1225–8.PubMedCrossRefGoogle Scholar
  56. 56.
    Kamar N, Izopet J, Tripon S, et al. Ribavirin for chronic hepatitis E virus infection in transplant recipients. N Engl J Med. 2014;370:1111–20.PubMedCrossRefGoogle Scholar
  57. 57.
    Riezebos-Brilman A, Puchhammer-Stockl E, van der Weide HY, et al. Chronic hepatitis E infection in lung transplant recipients. J Heart Lung Transplant. 2013;32:341–6.PubMedCrossRefGoogle Scholar
  58. 58.
    Pischke S, Hardtke S, Bode U, et al. Ribavirin treatment of acute and chronic hepatitis E: a single-centre experience. Liver Int. 2013;33:722–6.PubMedCrossRefGoogle Scholar
  59. 59.
    Lake KD, Smith CI, Milfred-La Forest SK, Pritzker MR, Emery RW. Outcomes of hepatitis C positive (HCV+) heart transplant recipients. Transplant Proc. 1997;29:581–2.PubMedCrossRefGoogle Scholar
  60. 60.
    Fong TL, Hou L, Hutchinson IV, Cicciarelli JC, Cho YW. Impact of hepatitis C infection on outcomes after heart transplantation. Transplantation. 2009;88:1137–41.PubMedCrossRefGoogle Scholar
  61. 61.
    Gasink LB, Blumberg EA, Localio AR, Desai SS, Israni AK, Lautenbach E. Hepatitis C virus seropositivity in organ donors and survival in heart transplant recipients. JAMA. 2006;296:1843–50.PubMedCrossRefGoogle Scholar
  62. 62.
    Kim EY, Ko HH, Yoshida EM. A concise review of hepatitis C in heart and lung transplantation. Can J Gastroenterol. 2011;25:445–8.PubMedPubMedCentralCrossRefGoogle Scholar
  63. 63.
    Delmonico FL. Cadaver donor screening for infectious agents in solid organ transplantation. Clin Infect Dis. 2000;31:781–6.PubMedCrossRefGoogle Scholar
  64. 64.
    Lunel F, Cadranel JF, Rosenheim M, et al. Hepatitis virus infections in heart transplant recipients: epidemiology, natural history, characteristics, and impact on survival. Gastroenterology. 2000;119:1064–74.PubMedCrossRefGoogle Scholar
  65. 65.
    Orens JB, Estenne M, Arcasoy S, et al. International guidelines for the selection of lung transplant candidates: 2006 update—a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2006;25:745–55.PubMedCrossRefGoogle Scholar
  66. 66.
    Manickam P, Krishnamoorthi R, Kanaan Z, Gunasekaran PK, Cappell MS. Prognostic implications of recipient or donor hepatitis B seropositivity in thoracic transplantation: analysis of 426 hepatitis B surface antigen-positive recipients. Transpl Infect Dis. 2014;16:597–604.PubMedCrossRefGoogle Scholar
  67. 67.
    Fishman JA. Overview: cytomegalovirus and the herpesviruses in transplantation. Am J Transplant. 2013;13 Suppl 3:1–8.PubMedCrossRefGoogle Scholar
  68. 68.
    Bate SL, Dollard SC, Cannon MJ. Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988–2004. Clin Infect Dis. 2010;50:1439–47.PubMedCrossRefGoogle Scholar
  69. 69.
    Humar A, Snydman D. Cytomegalovirus in solid organ transplant recipients. Am J Transplant. 2009;9 Suppl 4:S78–86.PubMedCrossRefGoogle Scholar
  70. 70.
    Beam E, Razonable RR. Cytomegalovirus in solid organ transplantation: epidemiology, prevention, and treatment. Curr Infect Dis Rep. 2012;14:633–41.PubMedCrossRefGoogle Scholar
  71. 71.
    Patel G, Huprikar S. Infectious complications after orthotopic liver transplantation. Semin Respir Crit Care Med. 2012;33:111–24.PubMedCrossRefGoogle Scholar
  72. 72.
    Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis. 2002;34:1094–7.PubMedCrossRefGoogle Scholar
  73. 73.
    Razonable RR, Humar A. Cytomegalovirus in solid organ transplantation. Am J Transplant. 2013;13 Suppl 4:93–106.PubMedCrossRefGoogle Scholar
  74. 74.
    Lautenschlager I. CMV infection, diagnosis and antiviral strategies after liver transplantation. Transpl Int. 2009;22:1031–40.PubMedCrossRefGoogle Scholar
  75. 75.
    Razonable R. Direct and indirect effects of cytomegalovirus: can we prevent them? Enferm Infecc Microbiol Clin. 2010;28:1–5.PubMedCrossRefGoogle Scholar
  76. 76.
    Snydman DR, Limaye AP, Potena L, Zamora MR. Update and review: state-of-the-art management of cytomegalovirus infection and disease following thoracic organ transplantation. Transplant Proc. 2011;43:S1–17.PubMedCrossRefGoogle Scholar
  77. 77.
    Smith C, Khanna R. Immune regulation of human herpesviruses and its implications for human transplantation. Am J Transplant. 2013;13 Suppl 3:9–23.PubMedCrossRefGoogle Scholar
  78. 78.
    Kute VB, Vanikar AV, Shah PR, et al. Post-renal transplant cytomegalovirus infection: study of risk factors. Transplant Proc. 2012;44:706–9.PubMedCrossRefGoogle Scholar
  79. 79.
    Kotton CN. CMV: prevention, diagnosis and therapy. Am J Transplant. 2013;13 Suppl 3:24–40.PubMedCrossRefGoogle Scholar
  80. 80.
    Eid AJ, Arthurs SK, Deziel PJ, Wilhelm MP, Razonable RR. Clinical predictors of relapse after treatment of primary gastrointestinal cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2010;10:157–61.PubMedCrossRefGoogle Scholar
  81. 81.
    Subramanian AK. Antimicrobial prophylaxis regimens following transplantation. Curr Opin Infect Dis. 2011;24:344–9.PubMedCrossRefGoogle Scholar
  82. 82.
    Asberg A, Humar A, Rollag H, et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2007;7:2106–13.PubMedCrossRefGoogle Scholar
  83. 83.
    Kawecki D, Kwiatkowski A, Sawicka-Grzelak A, et al. Urinary tract infections in the early posttransplant period after kidney transplantation: etiologic agents and their susceptibility. Transplant Proc. 2011;43:2991–3.PubMedCrossRefGoogle Scholar
  84. 84.
    Barbouch S, Cherif M, Ounissi M, et al. Urinary tract infections following renal transplantation: a single-center experience. Saudi J Kidney Dis Transpl. 2012;23:1311–4.PubMedGoogle Scholar
  85. 85.
    Cordero E, Casasola C, Ecarma R, Danguilan R. Cytomegalovirus disease in kidney transplant recipients: incidence, clinical profile, and risk factors. Transplant Proc. 2012;44:694–700.PubMedCrossRefGoogle Scholar
  86. 86.
    Cukuranovic J, Ugrenovic S, Jovanovic I, Visnjic M, Stefanovic V. Viral infection in renal transplant recipients. Sci World J. 2012;2012:820621.CrossRefGoogle Scholar
  87. 87.
    Stern M, Hirsch H, Cusini A, et al. Cytomegalovirus serology and replication remain associated with solid organ graft rejection and graft loss in the era of prophylactic treatment. Transplantation. 2014;98:1013–8.PubMedCrossRefGoogle Scholar
  88. 88.
    Arthurs SK, Eid AJ, Pedersen RA, et al. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis. 2008;46:840–6.PubMedCrossRefGoogle Scholar
  89. 89.
    Kusne S, Blair JE. Viral and fungal infections after liver transplantation—part II. Liver Transpl. 2006;12:2–11.PubMedCrossRefGoogle Scholar
  90. 90.
    Kotton CN, Kumar D, Caliendo AM, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation. 2010;89:779–95.PubMedCrossRefGoogle Scholar
  91. 91.
    Hibberd PL, Snydman DR. Cytomegalovirus infection in organ transplant recipients. Infect Dis Clin North Am. 1995;9:863–77.PubMedGoogle Scholar
  92. 92.
    Lautenschlager I, Halme L, Hockerstedt K, Krogerus L, Taskinen E. Cytomegalovirus infection of the liver transplant: virological, histological, immunological, and clinical observations. Transpl Infect Dis. 2006;8:21–30.PubMedCrossRefGoogle Scholar
  93. 93.
    Razonable RR. Cytomegalovirus infection after liver transplantation: current concepts and challenges. World J Gastroenterol. 2008;14:4849–60.PubMedPubMedCentralCrossRefGoogle Scholar
  94. 94.
    Marcelin JR, Beam E, Razonable RR. Cytomegalovirus infection in liver transplant recipients: updates on clinical management. World J Gastroenterol. 2014;20:10658–67.PubMedPubMedCentralCrossRefGoogle Scholar
  95. 95.
    Vivarelli M, De Ruvo N, Lazzarotto T, et al. Abstension from treatment of low-level pp 65 cytomegalovirus antigenemia after liver transplantation: a prospective study. Transplantation. 2000;70:1183–7.PubMedCrossRefGoogle Scholar
  96. 96.
    Rubin RH. The direct and indirect effects of infection in liver transplantation: pathogenesis, impact, and clinical management. Curr Clin Top Infect Dis. 2002;22:125–54.PubMedGoogle Scholar
  97. 97.
    Martelius T, Krogerus L, Hockerstedt K, Bruggeman C, Lautenschlager I. Cytomegalovirus infection is associated with increased inflammation and severe bile duct damage in rat liver allografts. Hepatology. 1998;27:996–1002.PubMedCrossRefGoogle Scholar
  98. 98.
    Manuel O, Kralidis G, Mueller NJ, et al. Impact of antiviral preventive strategies on the incidence and outcomes of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2013;13:2402–10.PubMedCrossRefGoogle Scholar
  99. 99.
    Gao LH, Zheng SS. Cytomegalovirus and chronic allograft rejection in liver transplantation. World J Gastroenterol. 2004;10:1857–61.PubMedPubMedCentralCrossRefGoogle Scholar
  100. 100.
    Husain S, Tollemar J, Dominguez EA, et al. Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: prospective, multicenter, case-controlled study. Transplantation. 2003;75:2023–9.PubMedCrossRefGoogle Scholar
  101. 101.
    Terrault N. Liver transplantation in the setting of chronic HCV. Best Pract Res Clin Gastroenterol. 2012;26:531–48.PubMedCrossRefGoogle Scholar
  102. 102.
    Xu F, Sternberg MR, Kottiri BJ, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA. 2006;296:964–73.PubMedCrossRefGoogle Scholar
  103. 103.
    Zuckerman RA, Limaye AP. Varicella Zoster Virus (VZV) and Herpes Simplex Virus (HSV) in solid organ transplant patients. Am J Transplant. 2013;13 Suppl 3:55–66.PubMedCrossRefGoogle Scholar
  104. 104.
    Wilck MB, Zuckerman RA. Herpes simplex virus in solid organ transplantation. Am J Transplant. 2013;13 Suppl 4:121–7.PubMedCrossRefGoogle Scholar
  105. 105.
    Netchiporouk E, Tchervenkov J, Paraskevas S, Sasseville D, Billick R. Evaluation of herpes simplex virus infection morbidity and mortality in pancreas and kidney-pancreas transplant recipients. Transplant Proc. 2013;45:3343–7.PubMedCrossRefGoogle Scholar
  106. 106.
    Ahsan N, Rao KV. Hepatobiliary diseases after kidney transplantation unrelated to classic hepatitis virus. Semin Dial. 2002;15:358–65.PubMedCrossRefGoogle Scholar
  107. 107.
    Basse G, Mengelle C, Kamar N, et al. Disseminated herpes simplex type-2 (HSV-2) infection after solid-organ transplantation. Infection. 2008;36:62–4.PubMedCrossRefGoogle Scholar
  108. 108.
    Singh N, Dummer JS, Kusne S, et al. Infections with cytomegalovirus and other herpesviruses in 121 liver transplant recipients: transmission by donated organ and the effect of OKT3 antibodies. J Infect Dis. 1988;158:124–31.PubMedPubMedCentralCrossRefGoogle Scholar
  109. 109.
    Dummer JS, Armstrong J, Somers J, et al. Transmission of infection with herpes simplex virus by renal transplantation. J Infect Dis. 1987;155:202–6.PubMedCrossRefGoogle Scholar
  110. 110.
    Montalbano M, Slapak-Green GI, Neff GW. Fulminant hepatic failure from herpes simplex virus: post liver transplantation acyclovir therapy and literature review. Transplant Proc. 2005;37:4393–6.PubMedCrossRefGoogle Scholar
  111. 111.
    Cote-Daigneault J, Carrier FM, Toledano K, Wartelle-Bladu C, Willems B. Herpes simplex hepatitis after liver transplantation: case report and literature review. Transpl Infect Dis. 2014;16:130–4.PubMedCrossRefGoogle Scholar
  112. 112.
    Ichai P, Roque Afonso AM, Sebagh M, et al. Herpes simplex virus-associated acute liver failure: a difficult diagnosis with a poor prognosis. Liver Transpl. 2005;11:1550–5.PubMedCrossRefGoogle Scholar
  113. 113.
    Fehr T, Bossart W, Wahl C, Binswanger U. Disseminated varicella infection in adult renal allograft recipients: four cases and a review of the literature. Transplantation. 2002;73:608–11.PubMedCrossRefGoogle Scholar
  114. 114.
    Gourishankar S, McDermid JC, Jhangri GS, Preiksaitis JK. Herpes zoster infection following solid organ transplantation: incidence, risk factors and outcomes in the current immunosuppressive era. Am J Transplant. 2004;4:108–15.PubMedCrossRefGoogle Scholar
  115. 115.
    Pergam SA, Forsberg CW, Boeckh MJ, et al. Herpes zoster incidence in a multicenter cohort of solid organ transplant recipients. Transpl Infect Dis. 2011;13:15–23.PubMedPubMedCentralCrossRefGoogle Scholar
  116. 116.
    Manuel O, Kumar D, Singer LG, Cobos I, Humar A. Incidence and clinical characteristics of herpes zoster after lung transplantation. J Heart Lung Transplant. 2008;27:11–6.PubMedCrossRefGoogle Scholar
  117. 117.
    Netchiporouk E, Tchervenkov J, Paraskevas S, Sasseville D, Billick R. Evaluation of varicella zoster virus infection morbidity and mortality in pancreas and kidney-pancreas transplant recipients. Transplant Proc. 2013;45:701–4.PubMedCrossRefGoogle Scholar
  118. 118.
    Fiddian P, Sabin CA, Griffiths PD. Valacyclovir provides optimum acyclovir exposure for prevention of cytomegalovirus and related outcomes after organ transplantation. J Infect Dis. 2002;186 Suppl 1:S110–5.PubMedCrossRefGoogle Scholar
  119. 119.
    Kusne S, Pappo O, Manez R, et al. Varicella-zoster virus hepatitis and a suggested management plan for prevention of VZV infection in adult liver transplant recipients. Transplantation. 1995;60:619–21.PubMedPubMedCentralCrossRefGoogle Scholar
  120. 120.
    Green M, Michaels MG. Epstein-Barr virus infection and posttransplant lymphoproliferative disorder. Am J Transplant. 2013;13 Suppl 3:41–54.PubMedCrossRefGoogle Scholar
  121. 121.
    Allen U, Preiksaitis J. Epstein-Barr virus and posttransplant lymphoproliferative disorder in solid organ transplant recipients. Am J Transplant. 2009;9 Suppl 4:S87–96.PubMedCrossRefGoogle Scholar
  122. 122.
    Green M, Webber S. Posttransplantation lymphoproliferative disorders. Pediatr Clin North Am. 2003;50:1471–91.PubMedCrossRefGoogle Scholar
  123. 123.
    Adams LA, Deboer B, Jeffrey G, Marley R, Garas G. Ganciclovir and the treatment of Epstein-Barr virus hepatitis. J Gastroenterol Hepatol. 2006;21:1758–60.PubMedCrossRefGoogle Scholar
  124. 124.
    Langnas AN, Markin RS, Inagaki M, et al. Epstein-Barr virus hepatitis after liver transplantation. Am J Gastroenterol. 1994;89:1066–70.PubMedGoogle Scholar
  125. 125.
    Israni AK, Zaun DA, Rosendale JD, Snyder JJ, Kasiske BL. OPTN/SRTR 2011 Annual Data Report: deceased organ donation. Am J Transplant. 2013;13 Suppl 1:179–98.PubMedCrossRefGoogle Scholar
  126. 126.
    Abu-Elmagd K, Reyes J, Bond G, et al. Clinical intestinal transplantation: a decade of experience at a single center. Ann Surg. 2001;234:404–16. discussion 16–7.PubMedPubMedCentralCrossRefGoogle Scholar
  127. 127.
    Abu-Elmagd KM, Zak M, Stamos JM, et al. De novo malignancies after intestinal and multivisceral transplantation. Transplantation. 2004;77:1719–25.PubMedCrossRefGoogle Scholar
  128. 128.
    Miloh T, Magid M, Yurovitsky A, et al. T-cell PTLD presenting as acalculous cholecystitis. Pediatr Transplant. 2008;12:717–20.PubMedCrossRefGoogle Scholar
  129. 129.
    Ariza-Heredia EJ, Razonable RR. Human herpes virus 8 in solid organ transplantation. Transplantation. 2011;92:837–44.PubMedCrossRefGoogle Scholar
  130. 130.
    Lautenschlager I, Razonable RR. Human herpesvirus-6 infections in kidney, liver, lung, and heart transplantation: review. Transpl Int. 2012;25:493–502.PubMedCrossRefGoogle Scholar
  131. 131.
    Razonable RR. Human herpesviruses 6, 7 and 8 in solid organ transplant recipients. Am J Transplant. 2013;13 Suppl 3:67–78.PubMedCrossRefGoogle Scholar
  132. 132.
    Razonable RR, Paya CV. The impact of human herpesvirus-6 and -7 infection on the outcome of liver transplantation. Liver Transpl. 2002;8:651–8.PubMedCrossRefGoogle Scholar
  133. 133.
    Lautenschlager I, Linnavuori K, Hockerstedt K. Human herpesvirus-6 antigenemia after liver transplantation. Transplantation. 2000;69:2561–6.PubMedCrossRefGoogle Scholar
  134. 134.
    Razonable RR, Lautenschlager I. Impact of human herpes virus 6 in liver transplantation. World J Hepatol. 2010;2:345–53.PubMedPubMedCentralCrossRefGoogle Scholar
  135. 135.
    Ohashi M, Sugata K, Ihira M, et al. Human herpesvirus 6 infection in adult living related liver transplant recipients. Liver Transpl. 2008;14:100–9.PubMedCrossRefGoogle Scholar
  136. 136.
    Rogers J, Rohal S, Carrigan DR, et al. Human herpesvirus-6 in liver transplant recipients: role in pathogenesis of fungal infections, neurologic complications, and outcome. Transplantation. 2000;69:2566–73.PubMedCrossRefGoogle Scholar
  137. 137.
    Abdel Massih RC, Razonable RR. Human herpesvirus 6 infections after liver transplantation. World J Gastroenterol. 2009;15:2561–9.PubMedPubMedCentralCrossRefGoogle Scholar
  138. 138.
    De Bolle L, Naesens L, De Clercq E. Update on human herpesvirus 6 biology, clinical features, and therapy. Clin Microbiol Rev. 2005;18:217–45.PubMedPubMedCentralCrossRefGoogle Scholar
  139. 139.
    Fernandez-Ruiz M, Kumar D, Husain S, et al. Utility of a monitoring strategy for human herpesviruses 6 and 7 viremia after liver transplantation: a randomized clinical trial. Transplantation. 2015;99:106–13.PubMedCrossRefGoogle Scholar
  140. 140.
    Benhammane H, Mentha G, Tschanz E, El Mesbahi O, Dietrich PY. Visceral Kaposi’s sarcoma related to human herpesvirus-8 in liver transplant recipient: case report and literature review. Case Rep Oncol Med. 2012;2012:137291.PubMedPubMedCentralGoogle Scholar
  141. 141.
    Christenson ES, Teply B, Agrawal V, Illei P, Gurakar A, Kanakry JA. Human herpesvirus 8-related primary effusion lymphoma after liver transplantation. Am J Transplant. 2015;15:2762.PubMedCrossRefGoogle Scholar
  142. 142.
    Patel A, Bishburg E, Zucker M, Tsang P, Nagarakanti S, Sabnani I. Concomitant Kaposi sarcoma and multicentric Castleman’s disease in a heart transplant recipient. Heart Lung. 2014;43:506–9.PubMedCrossRefGoogle Scholar
  143. 143.
    Luppi M, Barozzi P, Rasini V, et al. Severe pancytopenia and hemophagocytosis after HHV-8 primary infection in a renal transplant patient successfully treated with foscarnet. Transplantation. 2002;74:131–2.PubMedCrossRefGoogle Scholar
  144. 144.
    Regamey N, Hess V, Passweg J, et al. Infection with human herpesvirus 8 and transplant-associated gammopathy. Transplantation. 2004;77:1551–4.PubMedCrossRefGoogle Scholar
  145. 145.
    Park UJ, Hyun SK, Kim HT, Cho WH, Han SY. Successful treatment of disseminated adenovirus infection with ribavirin and intravenous immunoglobulin in an adult renal transplant recipient: a case report. Transplant Proc. 2015;47:791–3.PubMedCrossRefGoogle Scholar
  146. 146.
    Rady K, Walters G, Brown M, Talaulikar G. Allograft adenovirus nephritis. Clin Kidney J. 2014;7:289–92.PubMedPubMedCentralCrossRefGoogle Scholar
  147. 147.
    Bruminhent J, Athas DM, Hess BD, Flomenberg P. Disseminated adenovirus disease in heart transplant recipient presenting with conjunctivitis. Transpl Infect Dis. 2015;17:125–8.PubMedCrossRefGoogle Scholar
  148. 148.
    Lachiewicz AM, Cianciolo R, Miller MB, Derebail VK. Adenovirus causing fever, upper respiratory infection, and allograft nephritis complicated by persistent asymptomatic viremia. Transpl Infect Dis. 2014;16:648–52.PubMedCrossRefGoogle Scholar
  149. 149.
    Chakrabarti S, Mautner V, Osman H, et al. Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Blood. 2002;100:1619–27.PubMedCrossRefGoogle Scholar
  150. 150.
    Kerensky T, Hasan A, Schain D, et al. Histopathologic resolution of adult liver transplantation adenovirus hepatitis with cidofovir and intravenous immunoglobulin: a case report. Transplant Proc. 2013;45:293–6.PubMedCrossRefGoogle Scholar
  151. 151.
    Florescu DF, Kwon JY, Dumitru I. Adenovirus infections in heart transplantation. Cardiol Rev. 2013;21:203–6.PubMedCrossRefGoogle Scholar
  152. 152.
    Kim SI. Bacterial infection after liver transplantation. World J Gastroenterol. 2014;20:6211–20.PubMedPubMedCentralCrossRefGoogle Scholar
  153. 153.
    Kusne S, Dummer JS, Singh N, et al. Infections after liver transplantation. An analysis of 101 consecutive cases. Medicine. 1988;67:132–43.PubMedPubMedCentralCrossRefGoogle Scholar
  154. 154.
    Avkan-Oguz V, Ozkardesler S, Unek T, et al. Risk factors for early bacterial infections in liver transplantation. Transplant Proc. 2013;45:993–7.PubMedCrossRefGoogle Scholar
  155. 155.
    Ki HK, Son JS, Oh WS. Infectious complications after liver transplantation according to donor: comparison between orthotopic and living donor transplantation. Infect Chemother. 2004;36:139–47.Google Scholar
  156. 156.
    Sganga G, Bianco G, Fiori B, et al. Surveillance of bacterial and fungal infections in the postoperative period following liver transplantation: a series from 2005–2011. Transplant Proc. 2013;45:2718–21.PubMedCrossRefGoogle Scholar
  157. 157.
    Benson AB, Burton Jr JR, Austin GL, et al. Differential effects of plasma and red blood cell transfusions on acute lung injury and infection risk following liver transplantation. Liver Transpl. 2011;17:149–58.PubMedPubMedCentralCrossRefGoogle Scholar
  158. 158.
    Sanada Y, Urahashi T, Ihara Y, et al. Pretransplant levels of endotoxin can predict the risk of bacterial infections and graft liver function after liver transplantation. Eur J Pediatr Surg. 2015;25:236–41.PubMedGoogle Scholar
  159. 159.
    Singh N. Infectious complications in organ transplant recipients with the use of calcineurin-inhibitor agent-based immunosuppressive regimens. Curr Opin Infect Dis. 2005;18:342–5.PubMedCrossRefGoogle Scholar
  160. 160.
    Fishman JA, Issa NC. Infection in organ transplantation: risk factors and evolving patterns of infection. Infect Dis Clin North Am. 2010;24:273–83.PubMedCrossRefGoogle Scholar
  161. 161.
    Freire MP, Soares Oshiro IC, Bonazzi PR, et al. Surgical site infections in liver transplant recipients in the model for end-stage liver disease era: an analysis of the epidemiology, risk factors, and outcomes. Liver Transpl. 2013;19:1011–9.PubMedCrossRefGoogle Scholar
  162. 162.
    Dorschner P, McElroy LM, Ison MG. Nosocomial infections within the first month of solid organ transplantation. Transpl Infect Dis. 2014;16:171–87.PubMedCrossRefGoogle Scholar
  163. 163.
    Hellinger WC, Crook JE, Heckman MG, et al. Surgical site infection after liver transplantation: risk factors and association with graft loss or death. Transplantation. 2009;87:1387–93.PubMedCrossRefGoogle Scholar
  164. 164.
    Gastaca M. Biliary complications after orthotopic liver transplantation: a review of incidence and risk factors. Transplant Proc. 2012;44:1545–9.PubMedCrossRefGoogle Scholar
  165. 165.
    Verdonk RC, Buis CI, Porte RJ, Haagsma EB. Biliary complications after liver transplantation: a review. Scand J Gastroenterol Suppl. 2006;243:89–101.CrossRefGoogle Scholar
  166. 166.
    Poley JW, Lekkerkerker MN, Metselaar HJ, Kuipers EJ, Bruno MJ. Clinical outcome of progressive stenting in patients with anastomotic strictures after orthotopic liver transplantation. Endoscopy. 2013;45:567–70.PubMedCrossRefGoogle Scholar
  167. 167.
    Gotthardt DN, Weiss KH, Rupp C, et al. Bacteriobilia and fungibilia are associated with outcome in patients with endoscopic treatment of biliary complications after liver transplantation. Endoscopy. 2013;45:890–6.PubMedCrossRefGoogle Scholar
  168. 168.
    Jain A, Singhal A, Fontes P, et al. One thousand consecutive primary liver transplants under tacrolimus immunosuppression: a 17- to 20-year longitudinal follow-up. Transplantation. 2011;91:1025–30.PubMedCrossRefGoogle Scholar
  169. 169.
    Claridge LC, Dobson C, Kanji H, Neil D, Timms JM, Holt AP. Acute liver failure secondary to opportunistic viral infection in adult solid organ transplant recipients. QJM. 2012;105:879–82.PubMedCrossRefGoogle Scholar
  170. 170.
    Jafarian A, Kasraianfard A, Nassiri-Toosi M. Revision liver transplant for persistent infection and localized aspergillosis after hepatic artery thrombosis. Exp Clin Transplant. 2014;12:381–3.PubMedGoogle Scholar
  171. 171.
    Leithead JA, Smith MR, Materacki LB, et al. Intercurrent infection predicts mortality in patients with late hepatic artery thrombosis listed for liver retransplantation. Liver Transpl. 2012;18:1353–60.PubMedCrossRefGoogle Scholar
  172. 172.
    Lowell JA, Stratta RJ, Taylor RJ, Bynon JS, Larsen JL, Nelson NL. Cholelithiasis in pancreas and kidney transplant recipients with diabetes. Surgery. 1993;114:858–63.PubMedGoogle Scholar
  173. 173.
    Peterseim DS, Pappas TN, Meyers CH, Shaeffer GS, Meyers WC, Van Trigt P. Management of biliary complications after heart transplantation. J Heart Lung Transplant. 1995;14:623–31.PubMedGoogle Scholar
  174. 174.
    Gupta D, Sakorafas GH, McGregor CG, Harmsen WS, Farnell MB. Management of biliary tract disease in heart and lung transplant patients. Surgery. 2000;128:641–9.PubMedCrossRefGoogle Scholar
  175. 175.
    Loinaz C, Kato T, Nishida S, et al. Bacterial infections after intestine and multivisceral transplantation. Transplant Proc. 2003;35:1929–30.PubMedCrossRefGoogle Scholar
  176. 176.
    Tabarsi P, Farshidpour M, Marjani M, et al. Mycobacterial infection and the impact of rifabutin treatment in organ transplant recipients: a single-center study. Saudi J Kidney Dis Transpl. 2015;26:6–11.PubMedCrossRefGoogle Scholar
  177. 177.
    Karuthu S, Blumberg EA. Common infections in kidney transplant recipients. Clin J Am Soc Nephrol. 2012;7:2058–70.PubMedCrossRefGoogle Scholar
  178. 178.
    Lopez de Castilla D, Schluger NW. Tuberculosis following solid organ transplantation. Transpl Infect Dis. 2010;12:106–12.PubMedCrossRefGoogle Scholar
  179. 179.
    Fabrega E, Sampedro B, Cabezas J, et al. Chemoprophylaxis with isoniazid in liver transplant recipients. Liver Transpl. 2012;18:1110–7.PubMedCrossRefGoogle Scholar
  180. 180.
    Bodro M, Sabe N, Santin M, et al. Clinical features and outcomes of tuberculosis in solid organ transplant recipients. Transplant Proc. 2012;44:2686–9.PubMedCrossRefGoogle Scholar
  181. 181.
    Rasheed S, Zinicola R, Watson D, Bajwa A, McDonald PJ. Intra-abdominal and gastrointestinal tuberculosis. Colorectal Dis. 2007;9:773–83.PubMedCrossRefGoogle Scholar
  182. 182.
    Doucette K, Fishman JA. Nontuberculous mycobacterial infection in hematopoietic stem cell and solid organ transplant recipients. Clin Infect Dis. 2004;38:1428–39.PubMedCrossRefGoogle Scholar
  183. 183.
    Longworth SA, Vinnard C, Lee I, Sims KD, Barton TD, Blumberg EA. Risk factors for nontuberculous mycobacterial infections in solid organ transplant recipients: a case-control study. Transpl Infect Dis. 2014;16:76–83.PubMedCrossRefGoogle Scholar
  184. 184.
    Aguado JM, Torre-Cisneros J, Fortun J, et al. Tuberculosis in solid-organ transplant recipients: consensus statement of the group for the study of infection in transplant recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology. Clin Infect Dis. 2009;48:1276–84.PubMedCrossRefGoogle Scholar
  185. 185.
    Eschenauer GA, Lam SW, Carver PL. Antifungal prophylaxis in liver transplant recipients. Liver Transpl. 2009;15:842–58.PubMedCrossRefGoogle Scholar
  186. 186.
    Kriengkauykiat J, Ito JI, Dadwal SS. Epidemiology and treatment approaches in management of invasive fungal infections. Clin Epidemiol. 2011;3:175–91.PubMedPubMedCentralGoogle Scholar
  187. 187.
    Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis. 2010;50:1101–11.PubMedCrossRefGoogle Scholar
  188. 188.
    Shi SH, Lu AW, Shen Y, et al. Spectrum and risk factors for invasive candidiasis and non-Candida fungal infections after liver transplantation. Chin Med J (Engl). 2008;121:625–30.Google Scholar
  189. 189.
    Richardson M, Lass-Florl C. Changing epidemiology of systemic fungal infections. Clin Microbiol Infect. 2008;14 Suppl 4:5–24.PubMedCrossRefGoogle Scholar
  190. 190.
    Singh N, Wagener MM, Marino IR, Gayowski T. Trends in invasive fungal infections in liver transplant recipients: correlation with evolution in transplantation practices. Transplantation. 2002;73:63–7.PubMedCrossRefGoogle Scholar
  191. 191.
    Silveira FP, Kusne S. Candida infections in solid organ transplantation. Am J Transplant. 2013;13 Suppl 4:220–7.PubMedCrossRefGoogle Scholar
  192. 192.
    Patel R, Portela D, Badley AD, et al. Risk factors of invasive Candida and non-Candida fungal infections after liver transplantation. Transplantation. 1996;62:926–34.PubMedCrossRefGoogle Scholar
  193. 193.
    Marik PE. Fungal infections in solid organ transplantation. Expert Opin Pharmacother. 2006;7:297–305.PubMedCrossRefGoogle Scholar
  194. 194.
    Raghuram A, Restrepo A, Safadjou S, et al. Invasive fungal infections following liver transplantation: incidence, risk factors, survival, and impact of fluconazole-resistant Candida parapsilosis (2003–2007). Liver Transpl. 2012;18:1100–9.PubMedCrossRefGoogle Scholar
  195. 195.
    Yang CH, He XS, Chen J, et al. Fungal infection in patients after liver transplantation in years 2003 to 2012. Ann Transplant. 2012;17:59–63.PubMedCrossRefGoogle Scholar
  196. 196.
    Krause W, Matheis H, Wulf K. Fungaemia and funguria after oral administration of Candida albicans. Lancet. 1969;1:598–9.PubMedCrossRefGoogle Scholar
  197. 197.
    Kusne S, Tobin D, Pasculle AW, Van Thiel DH, Ho M, Starzl TE. Candida carriage in the alimentary tract of liver transplant candidates. Transplantation. 1994;57:398–402.PubMedPubMedCentralCrossRefGoogle Scholar
  198. 198.
    Guaraldi G, Cocchi S, Codeluppi M, et al. Outcome, incidence, and timing of infectious complications in small bowel and multivisceral organ transplantation patients. Transplantation. 2005;80:1742–8.PubMedCrossRefGoogle Scholar
  199. 199.
    Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:503–35.PubMedCrossRefGoogle Scholar
  200. 200.
    Liu X, Ling Z, Li L, Ruan B. Invasive fungal infections in liver transplantation. Int J Infect Dis. 2011;15:e298–304.PubMedCrossRefGoogle Scholar
  201. 201.
    Trudeau RE, Bowman LJ, Wills AR, Crippin JS, Chapman WC, Anderson C. Once weekly fluconazole for antifungal prophylaxis post-liver transplantation. HPB. 2013;15:541–7.PubMedCrossRefGoogle Scholar
  202. 202.
    Cruciani M, Mengoli C, Malena M, Bosco O, Serpelloni G, Grossi P. Antifungal prophylaxis in liver transplant patients: a systematic review and meta-analysis. Liver Transpl. 2006;12:850–8.PubMedCrossRefGoogle Scholar
  203. 203.
    Baddley JW, Andes DR, Marr KA, et al. Factors associated with mortality in transplant patients with invasive aspergillosis. Clin Infect Dis. 2010;50:1559–67.PubMedPubMedCentralCrossRefGoogle Scholar
  204. 204.
    Mazza D, Gugenheim J, Toouli J, Mouiel J. Survival of a liver graft recipient treated for an aspergillar liver abscess. Clin Infect Dis. 1996;23:831–2.PubMedCrossRefGoogle Scholar
  205. 205.
    Gupta KL, Rajaram KG, Joshi K, Sakhuja V. Progression of hepatic aspergillosis following second renal transplantation in a patient with recurrent glomerulonephritis. Indian J Pathol Microbiol. 2012;55:580–2.PubMedCrossRefGoogle Scholar
  206. 206.
    Hoyo I, Sanclemente G, de la Bellacasa JP, et al. Epidemiology, clinical characteristics, and outcome of invasive aspergillosis in renal transplant patients. Transpl Infect Dis. 2014;16:951–7.PubMedCrossRefGoogle Scholar
  207. 207.
    Ok Atilgan A, Ozdemir BH, Kirnap M, et al. Invasive fungal infections in liver transplant recipients. Exp Clin Transplant. 2014;12 Suppl 1:110–6.PubMedGoogle Scholar
  208. 208.
    Sganga G, Bianco G, Frongillo F, Lirosi MC, Nure E, Agnes S. Fungal infections after liver transplantation: incidence and outcome. Transplant Proc. 2014;46:2314–8.PubMedCrossRefGoogle Scholar
  209. 209.
    Vikram HR, Dosanjh A, Blair JE. Coccidioidomycosis and lung transplantation. Transplantation. 2011;92:717–21.PubMedCrossRefGoogle Scholar
  210. 210.
    Hayes Jr D, Ball AM, Mansour HM, Martin CA, Flynn JD. Fungal infection in heart-lung transplant recipients receiving single-agent prophylaxis with itraconazole. Exp Clin Transplant. 2011;9:399–404.PubMedGoogle Scholar
  211. 211.
    Doligalski CT, Benedict K, Cleveland AA, et al. Epidemiology of invasive mold infections in lung transplant recipients. Am J Transplant. 2014;14:1328–33.PubMedPubMedCentralCrossRefGoogle Scholar
  212. 212.
    Assi M, Martin S, Wheat LJ, et al. Histoplasmosis after solid organ transplant. Clin Infect Dis. 2013;57:1542–9.PubMedPubMedCentralCrossRefGoogle Scholar
  213. 213.
    Cuellar-Rodriguez J, Avery RK, Lard M, et al. Histoplasmosis in solid organ transplant recipients: 10 years of experience at a large transplant center in an endemic area. Clin Infect Dis. 2009;49:710–6.PubMedCrossRefGoogle Scholar
  214. 214.
    Swaika A, Ailawadhi S, Menke DM. Disseminated histoplasmosis in a renal transplant patient. Int J Hematol. 2014;100:315–6.PubMedCrossRefGoogle Scholar
  215. 215.
    Vucicevic D, Carey EJ, Blair JE. Coccidioidomycosis in liver transplant recipients in an endemic area. Am J Transplant. 2011;11:111–9.PubMedCrossRefGoogle Scholar
  216. 216.
    Petrikkos G, Skiada A, Drogari-Apiranthitou M. Epidemiology of mucormycosis in Europe. Clin Microbiol Infect. 2014;20 Suppl 6:67–73.PubMedCrossRefGoogle Scholar
  217. 217.
    Gurevich M, Levi I, Steinberg R, et al. Mucormycosis in a liver allograft: salvage re-transplantation and targeted immunosuppressive management. Transpl Infect Dis. 2012;14:E97–101.PubMedCrossRefGoogle Scholar
  218. 218.
    Singh N, Aguado JM, Bonatti H, et al. Zygomycosis in solid organ transplant recipients: a prospective, matched case-control study to assess risks for disease and outcome. J Infect Dis. 2009;200:1002–11.PubMedCrossRefGoogle Scholar
  219. 219.
    Wang EH, Partovi N, Levy RD, Shapiro RJ, Yoshida EM, Greanya ED. Pneumocystis pneumonia in solid organ transplant recipients: not yet an infection of the past. Transpl Infect Dis. 2012;14:519–25.PubMedCrossRefGoogle Scholar
  220. 220.
    List AF, Spier C, Greer J, et al. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol. 1993;11:1652–60.PubMedCrossRefGoogle Scholar
  221. 221.
    Chand N, Sanyal AJ. Sepsis-induced cholestasis. Hepatology. 2007;45:230–41.PubMedCrossRefGoogle Scholar
  222. 222.
    Vela CG, Cristol JP, Descomps B, Mourad G. Prospective study of lipid disorders in FK506-versus cyclosporine-treated renal transplant patients. Transplant Proc. 2000;32.Google Scholar
  223. 223.
    Siddiqui AR, Abbas Z, Luck NH, et al. Experience of fibrosing cholestatic hepatitis with hepatitis C virus in kidney transplant recipients. Transplant Proc. 2012;44:721–4.PubMedCrossRefGoogle Scholar
  224. 224.
    Mousa HM, Woodley FW. Gastroesophageal reflux in cystic fibrosis: current understandings of mechanisms and management. Curr Gastroenterol Rep. 2012;14:226–35.PubMedCrossRefGoogle Scholar
  225. 225.
    Akamatsu N, Sugawara Y, Hashimoto D. Biliary reconstruction, its complications and management of biliary complications after adult liver transplantation: a systematic review of the incidence, risk factors and outcome. Transpl Int. 2011;24:379–92.PubMedCrossRefGoogle Scholar
  226. 226.
    Seven G, Cinar K, Idilman R, et al. Endoscopic treatment of biliary complications following liver transplantation. Turk J Gastroenterol. 2014;25:156–61.PubMedCrossRefGoogle Scholar
  227. 227.
    Gor NV, Levy RM, Ahn J, Kogan D, Dodson SF, Cohen SM. Biliary cast syndrome following liver transplantation: predictive factors and clinical outcomes. Liver Transpl. 2008;14:1466–72.PubMedCrossRefGoogle Scholar
  228. 228.
    Shah JN, Haigh WG, Lee SP, et al. Biliary casts after orthotopic liver transplantation: clinical factors, treatment, biochemical analysis. Am J Gastroenterol. 2003;98:1861–7.PubMedCrossRefGoogle Scholar
  229. 229.
    Yang YL, Zhang C, Lin MJ, et al. Biliary casts after liver transplantation: morphology and biochemical analysis. World J Gastroenterol. 2013;19:7772–7.PubMedPubMedCentralCrossRefGoogle Scholar
  230. 230.
    Buck DG, Zajko AB. Biliary complications after orthotopic liver transplantation. Tech Vasc Interv Radiol. 2008;11:51–9.PubMedCrossRefGoogle Scholar
  231. 231.
    Kaplan B, Meier-Kriesche HU, Jacobs MG, et al. Prevalence of cytomegalovirus in the gastrointestinal tract of renal transplant recipients with persistent abdominal pain. Am J Kidney Dis. 1999;34:65–8.PubMedCrossRefGoogle Scholar
  232. 232.
    Pacholczyk M, Lagiewska B, Lisik W, et al. Liver transplantation for HCV cirrhosis; cautious optimism after 10 years of experience. Ann Transplant. 2012;17:5–10.PubMedGoogle Scholar
  233. 233.
    Yilmaz N, Shiffman ML, Stravitz RT, et al. A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation. Liver Transpl. 2007;13:975–83.PubMedCrossRefGoogle Scholar
  234. 234.
    Lui WH, Chou TC, Chang SS, Hung CJ, Lin YJ, Lee PC. Peliosis hepatis in a kidney transplant recipient with manifestation as massive ascites and liver dysfunction: case report. Transplant Proc. 2014;46:630–3.PubMedCrossRefGoogle Scholar
  235. 235.
    Yu CY, Chang LC, Chen LW, et al. Peliosis hepatis complicated by portal hypertension following renal transplantation. World J Gastroenterol. 2014;20:2420–5.PubMedPubMedCentralCrossRefGoogle Scholar
  236. 236.
    Gotthardt DN, Weiss KH, Rathenberg V, Schemmer P, Stremmel W, Sauer P. Persistent ascites after liver transplantation: etiology, treatment and impact on survival. Ann Transplant. 2013;18:378–83.PubMedCrossRefGoogle Scholar
  237. 237.
    Nishida S, Gaynor JJ, Nakamura N, et al. Refractory ascites after liver transplantation: an analysis of 1058 liver transplant patients at a single center. Am J Transplant. 2006;6:140–9.PubMedCrossRefGoogle Scholar
  238. 238.
    Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009;15:1143–238.PubMedPubMedCentralCrossRefGoogle Scholar
  239. 239.
    Strasser SI, Myerson D, Spurgeon CL, et al. Hepatitis C virus infection and bone marrow transplantation: a cohort study with 10-year follow-up. Hepatology. 1999;29:1893–9.PubMedCrossRefGoogle Scholar
  240. 240.
    Mallet V, Van Bommel F, Doerig C, Pischke S, Hermine O, Locasciulli A, Cordonnier C, Berg T, Moradpour D, Wedemeyer H, Ljungman P. Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukemia (ECIL-5). Lancet Infectious Diseases 2016;16:606–17.Google Scholar
  241. 241.
    Arcaini L, Vallisa D, Rattotti S, et al. Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi. Ann Oncol. 2014;25:1404–10.PubMedCrossRefGoogle Scholar
  242. 242.
    McDonald GB. Hepatobiliary complications of hematopoietic cell transplantation, 40 years on. Hepatology. 2010;51:1450–60.PubMedPubMedCentralCrossRefGoogle Scholar
  243. 243.
    Carpenter PA, Huang ML, McDonald GB. Activation of occult hepatitis B from a seronegative patient after hematopoietic cell transplant: a cautionary tale. Blood. 2002;99:4245–6.PubMedCrossRefGoogle Scholar
  244. 244.
    Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology. 2008;48:418–31.PubMedCrossRefGoogle Scholar
  245. 245.
    Dienstag JL, Ghany MG, Morgan TR, et al. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology. 2011;54:396–405.PubMedPubMedCentralCrossRefGoogle Scholar
  246. 246.
    Talwalkar JA, Kurtz DM, Schoenleber SJ, West CP, Montori VM. Ultrasound-based transient elastography for the detection of hepatic fibrosis: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2007;5:1214–20.PubMedCrossRefGoogle Scholar
  247. 247.
    Hamidieh AA, Shazad B, Ostovaneh MR, et al. Noninvasive measurement of liver fibrosis using transient elastography in pediatric patients with major thalassemia who are candidates for hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2014;20:1912–7.PubMedCrossRefGoogle Scholar
  248. 248.
    Auberger J, Graziadei I, Clausen J, Vogel W, Nachbaur D. Non-invasive transient elastography for the prediction of liver toxicity following hematopoietic SCT. Bone Marrow Transplant. 2013;48:159–60.PubMedCrossRefGoogle Scholar
  249. 249.
    Shuhart MC, Myerson D, Childs BH, et al. Marrow transplantation from hepatitis C virus seropositive donors: transmission rate and clinical course. Blood. 1994;84:3229–35.PubMedGoogle Scholar
  250. 250.
    Vance EA, Soiffer RJ, McDonald GB, Myerson D, Fingeroth J, Ritz J. Prevention of transmission of hepatitis C virus in bone marrow transplantation by treating the donor with alpha-interferon. Transplantation. 1996;62:1358–60.PubMedCrossRefGoogle Scholar
  251. 251.
    Surapaneni SN, Hari P, Knox J, Daniel J, Saeian K. Suppressive anti-HCV therapy for prevention of donor to recipient transmission in stem cell transplantation. Am J Gastroenterol. 2007;102:449–51.PubMedCrossRefGoogle Scholar
  252. 252.
    Beckerich F, Hezode C, Robin C, et al. New nucleotide polymerase inhibitors to rapidly permit hematopoietic stem cell donation from a positive HCV-RNA donor. Blood. 2014;124:2613–4.PubMedPubMedCentralCrossRefGoogle Scholar
  253. 253.
    Hsiao HH, Liu YC, Wang HC, et al. Hepatitis C transmission from viremic donors in hematopoietic stem cell transplant. Transpl Infect Dis. 2014;16:1003–6.PubMedCrossRefGoogle Scholar
  254. 254.
    Hui C-k, Lie A, Au W-y, et al. Effectiveness of prophylactic Anti-HBV therapy in allogeneic hematopoietic stem cell transplantation with HBsAg positive donors. Am J Transplant. 2005;5:1437–45.PubMedCrossRefGoogle Scholar
  255. 255.
    Piekarska A, Zaucha JM, Hellman A, McDonald GB. Prevention of hepatitis B virus (HBV) transmission from an infected stem cell donor. Bone Marrow Transplant. 2007;40:399–400.PubMedCrossRefGoogle Scholar
  256. 256.
    Deschenes M, Laneuville P. Pre-emptive use of lamivudine in bone marrow transplantation with chronic hepatitis B virus infection. Hepatology. 2004;39:867–8.PubMedCrossRefGoogle Scholar
  257. 257.
    Launay O, van der Vliet D, Rosenberg AR, et al. Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial. JAMA. 2011;305:1432–40.PubMedCrossRefGoogle Scholar
  258. 258.
    Said ZN. An overview of occult hepatitis B virus infection. World J Gastroenterol. 2011;17:1927–38.PubMedPubMedCentralCrossRefGoogle Scholar
  259. 259.
    Launay O, Masurel J, Servant-Delmas A, et al. High levels of serum hepatitis B virus DNA in patients with ‘anti-HBc alone’: role of HBsAg mutants. J Viral Hepat. 2011;18:721–9.PubMedCrossRefGoogle Scholar
  260. 260.
    EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012;57:167–85.Google Scholar
  261. 261.
    Lau GK, Suri D, Liang R, et al. Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen. Gastroenterology. 2002;122:614–24.PubMedCrossRefGoogle Scholar
  262. 262.
    Ilan Y, Nagler A, Zeira E, Adler R, Slavin S, Shouval D. Maintenance of immune memory to the hepatitis B envelope protein following adoptive transfer of immunity in bone marrow transplant recipients. Bone Marrow Transplant. 2000;26:633–8.PubMedCrossRefGoogle Scholar
  263. 263.
    Versluis J, Pas SD, Agteresch HJ, et al. Hepatitis E virus: an underestimated opportunistic pathogen in recipients of allogeneic hematopoietic stem cell transplantation. Blood. 2013;122:1079–86.PubMedCrossRefGoogle Scholar
  264. 264.
    Koenecke C, Pischke S, Beutel G, et al. Hepatitis E virus infection in a hematopoietic stem cell donor. Bone Marrow Transplant. 2014;49:159–60.PubMedCrossRefGoogle Scholar
  265. 265.
    Chakvetadze C, Mallet V, Gaussec L, Hannoun L, Pol S. Acute hepatitis A virus infection without IgM antibodies to hepatitis A virus. Ann Intern Med. 2011;154:507–8.PubMedCrossRefGoogle Scholar
  266. 266.
    Sakai M, Strasser SI, Shulman HM, McDonald SJ, Schoch HG, McDonald GB. Severe hepatocellular injury after hematopoietic cell transplant: incidence, etiology and outcome. Bone Marrow Transplant. 2009;44:441–7.PubMedPubMedCentralCrossRefGoogle Scholar
  267. 267.
    Evans AT, Loeb KR, Shulman HM, et al. Fibrosing cholestatic hepatitis C after hematopoietic cell transplantation: report of 3 fatal cases. Am J Surg Pathol. 2015;39:212–20.PubMedCrossRefGoogle Scholar
  268. 268.
    Kamar N, Bendall R, Legrand-Abravanel F, et al. Hepatitis E. Lancet. 2012;379:2477–88.PubMedCrossRefGoogle Scholar
  269. 269.
    le Coutre P, Meisel H, Hofmann J, et al. Reactivation of hepatitis E infection in a patient with acute lymphoblastic leukaemia after allogeneic stem cell transplantation. Gut. 2009;58:699–702.PubMedCrossRefGoogle Scholar
  270. 270.
    Yagi T, Karasuno T, Hasegawa T, et al. Acute abdomen without cutaneous signs of varicella zoster virus infection as a late complication of allogeneic bone marrow transplantation: importance of empiric therapy with acyclovir. Bone Marrow Transplant. 2000;25:1003–5.PubMedCrossRefGoogle Scholar
  271. 271.
    Vyas JM, Marasco WA. Fatal fulminant hepatic failure from adenovirus in allogeneic bone marrow transplant patients. Case Rep Infect Dis. 2012;2012:463569.PubMedPubMedCentralGoogle Scholar
  272. 272.
    Neofytos D, Ojha A, Mookerjee B, et al. Treatment of adenovirus disease in stem cell transplant recipients with cidofovir. Biol Blood Marrow Transplant. 2007;13:74–81.PubMedCrossRefGoogle Scholar
  273. 273.
    Muller WJ, Levin MJ, Shin YK, et al. Clinical and in vitro evaluation of cidofovir for treatment of adenovirus infection in pediatric hematopoietic stem cell transplant recipients. Clin Infect Dis. 2005;41:1812–6.PubMedCrossRefGoogle Scholar
  274. 274.
    Lindemans CA, Leen AM, Boelens JJ. How I treat adenovirus in hematopoietic stem cell transplant recipients. Blood. 2010;116:5476–85.PubMedPubMedCentralCrossRefGoogle Scholar
  275. 275.
    Wy Ip W, Qasim W. Management of adenovirus in children after allogeneic hematopoietic stem cell transplantation. Adv Hematol. 2013;2013:176418.PubMedPubMedCentralCrossRefGoogle Scholar
  276. 276.
    Walls T, Hawrami K, Ushiro-Lumb I, Shingadia D, Saha V, Shankar AG. Adenovirus infection after pediatric bone marrow transplantation: is treatment always necessary? Clin Infect Dis. 2005;40:1244–9.PubMedCrossRefGoogle Scholar
  277. 277.
    Koc Y, Miller KB, Schenkein DP, et al. Varicella zoster virus infections following allogeneic bone marrow transplantation: frequency, risk factors, and clinical outcome. Biol Blood Marrow Transpl. 2000;6:44–9.CrossRefGoogle Scholar
  278. 278.
    Green ML, Leisenring W, Stachel D, et al. Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012;18:1687–99.PubMedPubMedCentralCrossRefGoogle Scholar
  279. 279.
    Rees GM, Sarmiento JI, Myerson D, Coen D, Meyers JD, McDonald GB. Cytomegalovirus hepatitis in marrow transplant patients: clinical, histologic and histochemical analysis. Gastroenterology. 1990;98:A470.CrossRefGoogle Scholar
  280. 280.
    Murakami CS, Louie W, Chan GS, et al. Biliary obstruction in hematopoietic cell transplant recipients: an uncommon diagnosis with specific causes. Bone Marrow Transplant. 1999;23:921–7.PubMedCrossRefGoogle Scholar
  281. 281.
    Lau GK, He M-L, Fong DYT, et al. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology. 2002;36:702–9.PubMedCrossRefGoogle Scholar
  282. 282.
    Shang J, Wang H, Sun J, et al. A comparison of lamivudine vs. entecavir for prophylaxis of hepatitis B virus reactivation in allogeneic hematopoietic stem cell transplantation recipients: a single institutional experience. Bone Marrow Transplant 2016; 51: 581–6.Google Scholar
  283. 283.
    Milazzo L, Corbellino M, Foschi A, et al. Late onset of hepatitis B virus reactivation following hematopoietic stem cell transplantation: successful treatment with combined entecavir plus tenofovir therapy. Transpl Infect Dis. 2012;14:95–8.PubMedCrossRefGoogle Scholar
  284. 284.
    Tsang SW, Chan HL, Leung NW, et al. Lamivudine treatment for fulminant hepatic failure due to acute exacerbation of chronic hepatitis B infection. Aliment Pharmacol Ther. 2001;15:1737–44.PubMedCrossRefGoogle Scholar
  285. 285.
    Hui CK, Cheung WWW, Au WY, et al. Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut. 2005;54:1597–603.PubMedPubMedCentralCrossRefGoogle Scholar
  286. 286.
    Lin P-C, Poh S-B, Lee M-Y, Hsiao L-T, Chen P-M, Chiou T-J. Fatal fulminant hepatitis B after withdrawal of prophylactic lamivudine in hematopoietic stem cell transplantation patients. Int J Hematol. 2005;81:349–51.PubMedCrossRefGoogle Scholar
  287. 287.
    Hogan WJ, Maris M, Storer B, et al. Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients. Blood. 2004;103:78–84.PubMedCrossRefGoogle Scholar
  288. 288.
    Ramos CA, Saliba RM, de Padua L, et al. Impact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Haematologica. 2009;94:249–57.PubMedPubMedCentralCrossRefGoogle Scholar
  289. 289.
    Nakasone H, Kurosawa S, Yakushijin K, et al. Impact of hepatitis C virus infection on clinical outcome in recipients after allogeneic hematopoietic cell transplantation. Am J Hematol. 2013;88:477–84.PubMedCrossRefGoogle Scholar
  290. 290.
    Tomblyn M, Chen M, Kukreja M, et al. No increased mortality from donor or recipient hepatitis B- and/or hepatitis C-positive serostatus after related-donor allogeneic hematopoietic cell transplantation. Transpl Infect Dis. 2012;14:468–78.PubMedPubMedCentralCrossRefGoogle Scholar
  291. 291.
    Torres HA, Davila M. Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. Nat Rev Clin Oncol. 2012;9:156–66.PubMedCrossRefGoogle Scholar
  292. 292.
    Mahale P, Kontoyiannis DP, Chemaly RF, et al. Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients. J Hepatol. 2012;57:1177–85.PubMedCrossRefGoogle Scholar
  293. 293.
    Garg V, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology. 2011;54:20–7.PubMedCrossRefGoogle Scholar
  294. 294.
    Coilly A, Roche B, Dumortier J, et al. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. J Hepatol. 2014;60: 78–86.PubMedCrossRefGoogle Scholar
  295. 295.
    Tischer S, Fontana RJ. Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting. J Hepatol. 2014;60:872–84.PubMedCrossRefGoogle Scholar
  296. 296.
    Tavitian S, Peron JM, Huynh A, et al. Hepatitis E virus excretion can be prolonged in patients with hematological malignancies. J Clin Virol. 2010;49:141–4.PubMedCrossRefGoogle Scholar
  297. 297.
    Ljungman P, Johansson N, Aschan J, et al. Long-term effects of hepatitis C virus infection in allogeneic bone marrow transplant recipients. Blood. 1995;86:1614–8.PubMedGoogle Scholar
  298. 298.
    Tomas JF, Pinilla I, Garcia-Buey ML, et al. Long-term liver dysfunction after allogeneic bone marrow transplantation: clinical features and course in 61 patients. Bone Marrow Transplant. 2000;26:649–55.PubMedCrossRefGoogle Scholar
  299. 299.
    Strasser SI, Sullivan KM, Myerson D, et al. Cirrhosis of the liver in long-term marrow transplant survivors. Blood. 1999;93:3259–66.PubMedGoogle Scholar
  300. 300.
    Peffault de Latour R, Levy V, Asselah T, et al. Long-term outcome of hepatitis C infection after bone marrow transplantation. Blood. 2004;103:1618–24.PubMedCrossRefGoogle Scholar
  301. 301.
    Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–2.PubMedPubMedCentralCrossRefGoogle Scholar
  302. 302.
    Bruix J, Han KH, Gores G, Llovet JM, Mazzaferro V. Liver cancer: approaching a personalized care. J Hepatol. 2015;62:S144–56.PubMedPubMedCentralCrossRefGoogle Scholar
  303. 303.
    Shimizu T, Kasahara M, Tanaka K. Living-donor liver transplantation for chronic hepatic graft-versus-host disease. N Engl J Med. 2006;354:1536–7.PubMedCrossRefGoogle Scholar
  304. 304.
    Andreoni KA, Lin JI, Groben PA. Liver transplantation 27 years after bone marrow transplantation from the same living donor. N Engl J Med. 2004;350:2624–5.PubMedCrossRefGoogle Scholar
  305. 305.
    Nieters A, Kallinowski B, Brennan P, et al. Hepatitis C and risk of lymphoma: results of the European multicenter case-control study EPILYMPH. Gastroenterology. 2006;131:1879–86.PubMedCrossRefGoogle Scholar
  306. 306.
    Gisbert JP, Garcia-Buey L, Pajares JM, Moreno-Otero R. Systematic review: regression of lymphoproliferative disorders after treatment for hepatitis C infection. Aliment Pharmacol Ther. 2005;21:653–62.PubMedCrossRefGoogle Scholar
  307. 307.
    Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661–2.PubMedCrossRefGoogle Scholar
  308. 308.
    EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227–42.Google Scholar
  309. 309.
    Liaw Y-F, Kao J-H, Piratvisuth T, Chan HLY, Chien R-N, Liu C-J, Gane E, Locarnini S, Lim S-G, Han K-H, Amarapurkar D, Cooksley G, Jafri W, Mohammed R, Hou J-L, Chuang W-L, Lesmana LA, Sollano JD, Suh D-J, Omata M. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012;6:531–61.PubMedCrossRefGoogle Scholar
  310. 310.
    McDonald GB, Frieze D. A problem-oriented approach to liver disease in oncology patients. Gut. 2008;57:987–1003.PubMedCrossRefGoogle Scholar
  311. 311.
    Lok AS, Ward JW, Perrillo RP, McMahon BJ, Liang TJ. Reactivation of hepatitis B during immunosuppressive therapy: potentially fatal yet preventable. Ann Intern Med. 2012;156:743–5.PubMedPubMedCentralCrossRefGoogle Scholar
  312. 312.
    Hoffmeister PA, Storer BE, McDonald GB, Baker KS. Gallstones in pediatric hematopoietic cell transplant survivors with up to 40 years of follow-up. J Pediatr Hematol Oncol. 2014;36:484–90.PubMedPubMedCentralCrossRefGoogle Scholar
  313. 313.
    Peters M, Schurman D, Mayr AC, Hetzer R, Pohle HD, Ruf B. Immunosuppression and mycobacteria other then Mycobacterium tuberculosis: results from patients with and without HIV infection. Epidemiol Infect. 1989;103:293–300.PubMedPubMedCentralCrossRefGoogle Scholar
  314. 314.
    Skinner R, Appleton AL, Sprott MS, et al. Disseminated BCG infection in severe combined immunodeficiency presenting with severe anaemia and associated with gross hypersplenism after bone marrow transplantation. Bone Marrow Transplant. 1996;17:877–80.PubMedGoogle Scholar
  315. 315.
    Ko CW, Murakami C, Sekijima JH, Kim MH, McDonald GB, Lee SP. Chemical composition of gallbladder sludge in patients after marrow transplantation. Am J Gastroenterol. 1996;91:1207–10.PubMedGoogle Scholar
  316. 316.
    Ko CW, Gooley T, Schoch HG, et al. Acute pancreatitis in marrow transplant patients: prevalence at autopsy and risk factor analysis. Bone Marrow Transplant. 1997;20:1081–6.PubMedCrossRefGoogle Scholar
  317. 317.
    Alnusair MM, DeMagalhaes-Silverman M, Silverman WB. The role of ERCP in patients with pancreatico-biliary problems in the setting of hematopoietic stem cell transplant. Gastrointest Endosc. 2006;63:655–9.PubMedCrossRefGoogle Scholar
  318. 318.
    Kim HN, Alousi AM, Lee JH, Qiao W, Xiao L, Ross WA. Role of ERCP in patients after hematopoietic stem cell transplantation. Gastrointest Endosc. 2011;74:817–24.PubMedCrossRefGoogle Scholar
  319. 319.
    Hingorani SR, Guthrie K, Batchelder A, et al. Acute renal failure after myeloablative hematopoietic cell transplant: incidence and risk factors. Kidney Int. 2005;67:272–7.PubMedCrossRefGoogle Scholar
  320. 320.
    van Burik JH, Leisenring W, Myerson D, et al. The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis: an autopsy study of 355 patients. Medicine. 1998;77:246–54.PubMedCrossRefGoogle Scholar
  321. 321.
    Azie N, Neofytos D, Pfaller M, Meier-Kriesche HU, Quan SP, Horn D. The PATH (Prospective Antifungal Therapy) Alliance(R) registry and invasive fungal infections: update 2012. Diagn Microbiol Infect Dis. 2012;73:293–300.PubMedCrossRefGoogle Scholar
  322. 322.
    Rossetti F, Brawner DL, Bowden RA, et al. Fungal liver infection in marrow transplant patients: prevalence at autopsy, predisposing factors, and clinical features. Clin Infect Dis. 1995;20:801–11.PubMedCrossRefGoogle Scholar
  323. 323.
    Marotta G, Tozzi M, Sammassimo S, et al. Complete resolution of hepatic aspergillosis after non-myeloablative hematopoietic stem cell transplantation in a patient with acute myeloid leukemia. Hematology. 2005;10:383–6.PubMedCrossRefGoogle Scholar
  324. 324.
    Oliver MR, Van Voorhis WC, Boeckh M, Mattson D, Bowden RA. Hepatic mucormycosis in a bone marrow transplant recipient who ingested naturopathic medicine. Clin Infect Dis. 1996;22:521–4.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Clinical Professor of Medicine, University of Washington HepatologyNorthwest Hospital & Medical Center SeattleWashingtonUSA
  2. 2.Professor of Medicine, Division of Gastroenterology, University of Washington Member, Gastroenterology/HepatologySection, Clinical Research DivisionWashingtonUSA
  3. 3.Clinical Research DivisionFred Hutchinson Cancer Research CenterSeattleUSA
  4. 4.Department of MedicineUniversity of Washington School of MedicineSeattleUSA
  5. 5.Gastroenterology/Hepatology Section (D5-114)Fred Hutchinson Cancer Research CenterSeattleUSA

Personalised recommendations